US FDA approves Nuvation Bio's lung cancer therapy-March 2024-www.financetom.com

US FDA approves Nuvation Bio's lung cancer therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025 10:38 AM

June 11 (Reuters) - The U.S. Food and Drug

Administration said on Wednesday it has approved Nuvation Bio's ( NUVB )

therapy for patients with a type of lung cancer.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini

Ganguli)

Previous page： Market Chatter: Rakuten Considers US IPO of Credit Card Business Next page： Merck Says Data From Late-Stage Studies Show Investigational Two-Drug HiV Therapy Maintains Viral Suppression

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Rakuten Considers US IPO of Credit Card Business

Oct 15, 2025

07:42 AM EDT, 10/15/2025 (MT Newswires) -- Rakuten is reportedly looking to take its credit card business public in the US, Reuters reported Wednesday, citing two sources familiar with the matter. The Japanese e-commerce and financial services company is also considering a partial sale to a strategic player, the report added. Rakuten didn't immediately reply to MT Newswires' request for...

Merck Says Data From Late-Stage Studies Show Investigational Two-Drug HiV Therapy Maintains Viral Suppression

Oct 15, 2025

07:40 AM EDT, 10/15/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday that data from two late-stage studies of the investigational two-drug regimen of doravirine and islatravir in adults with HIV-1 infection that had been virologically suppressed in previous trials maintained viral suppression and demonstrated non-inferiority to a commonly used three-drug regimen. The once-daily, orally ingested drug showed no...

Abbott misses revenue expectations on weak demand for diagnostic devices

Oct 15, 2025

(Reuters) -Abbott's quarterly revenue fell short of analysts' expectations on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices. Shares of the company dropped nearly 3% premarket following the results. Abbott's total revenue of $11.37 billion, slightly missed analysts' average estimate of $11.40 billion, according to data compiled by LSEG. Sales...

Morgan Stanley Q3 Earnings, Net Revenue Rise

Oct 15, 2025

07:41 AM EDT, 10/15/2025 (MT Newswires) -- Morgan Stanley ( MS ) reported Q3 earnings Wednesday of $2.80 per diluted share, up from $1.88 a year earlier. Analysts polled by FactSet expected $2.08. Net revenue for the quarter ended Sept. 30 was $18.22 billion, compared with $15.38 billion a year earlier. Analysts surveyed by FactSet expected $16.69 billion. Shares of...